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ANXIETY AND ITS PHARMACOLOGIC CONTROL 
ROBERT R. SCHOPBACH, M.D.* 
"Peace be unto you." This has been an esteemed greeting from the earliest of 
times, and is indicative of man's great desire to obtain inner peace. However, anxiety, 
considered by some to be inherent in mankind, arises from time to time to disturb 
this state of inner peace. To reduce the frequency and severity of these disturbances 
man is constantly seeking additional calming measures. Reliance upon the protection 
of someone more powerful be that mother, spouse, or God, increases one's feeling of 
personal security. The measures in which we are more directly interested are those 
which serve to reduce the awareness of the disturbance and to reduce the physical 
responses to those stimuli. Frequently, new drugs are introduced as solving this 
problem only to fade into lesser positions later. 
Probably the oldest and best liked sedative is alcohol. It is utflized much more 
than some realize to quiet jangled nerves. Unfortunately it is frequently habituating 
and has toxic side effects which are well known. The barbiturates are dispensed as 
if they were nearly harmless. However, here also habituation is common and close 
supervision and concern by the physician is necessary. Convulsions and other with-
drawal reactions to barbiturates must be considered. Of the standard drugs, paraldehyde 
and chloral hydrate are the most desirable. Chloral hydrate is now avaflable in a 
palatable liquid, 0.5 gm. capsules and tablets. Two recent additions to the long list 
of sedatives are methyl-prylon (Noludar) and glutethimide (Doriden) which are 
moderately potent and non-barbituric. 
AMPHETAMINES A N D RELATED COMPOUNDS 
Sympathomimetic drugs and central nervous system stimulants are usually neglected 
as agents for reducing anxiety on the assumption that they would only increase tension. 
!n certain depressive states the reverse is true as the agitation is secondary to the 
depression. To those unfamfliar with this response it is quite surprising to see a 
restless, agitated patient, when given amphetamines intravenously, begin to calm down 
within a few minutes, to smile, and to verbalize his pleasure with the subjective mood 
changes. This occurs only in those depressions having a strong affective component 
(reactive, so-cafled involutional, or manicdepressive, depressed). The neurotic de-
pressives, where the depression is only one of a group of symptoms, do not obtain 
such relief but often experience an aggravation of their anxiety. This difference in 
reacting to the amphetamines can be utilized to help differentiate between these 
groups. For such a test 20 mgm. benzedrine (or its equivalent) is injected intravenously 
early in the morning when the affective depressions are usually worst. The response 
should be clear within 15-30 minutes. I f the medication proves effective, it might 
thereafter be given orally upon arising and at noon. I f given later in the day, it may 
impair sleep. I f the depression is severe, the patient should, of course, be hospitalized 
and probably be treated with electro-shock therapy. 
Some doctors hesitate to utilize these drugs in hypertensive individuals; however, 
I have never seen any marked elevations of blood pressures. Quite to the contrary, 
the blood pressure often decreases as the agitated depression is alleviated. Likewise. 
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appetite is improved rather than decreased as when amphetamines are taken by 
"normal" persons. This group of medications should be kept in mind and used as 
frequently as possible to reduce anxiety instead of barbflurates which sedate and may 
aggravate depressions. 
AZACYCLONOL (FRENQUEL) 
Frenquel is a piperdyl isomer of pipradiol hydrochloride (Meratran). It was found 
very effective in alleviating the experimental psychoses produced by mescaline sulfate 
and lysergic acid diamine. Because these experimental psychoses somewhat suggested 
schizophrenic episodes, it was felt that this drug might have a similar effect upon 
schizophrenic hallucinations and delusions. The initial work done by Fabing' at 
Cincinnati was most encouraging, but few people^ have been able to duplicate his work. 
Rinaldi^ stated it was most helpful in acute schizophrenic episodes, in other acute 
transient delusional states, and in postoperative confusional states. A group of in-
dividuals using this medication met in April 1956 and were almost unanimous in finding 
that the oral use of this medicine to be of no avafl. It was then suggested that the 
difficulty was in using it orafly instead of intravenously. I have subsequently prescribed 
it intravenously and still found it to be of no avail, even when used in acute situations. 
All seem agreed that it is of no value in the chronic schizophrenic. It may be that 
this drug wifl prove to have some value, but at present the most that can be said is 
that it does not cause any deleterious side effects. 
RAUWOLFIA 
Rauwolfia and related compounds were introduced in 1954-1955. In institutional-
ized patients Rauwolfia greatly reduced hyperactivity and aggressivity. However, in 
the greater number of anxious persons who were managing to adjust with varying 
success outside of hospitals, response was not as gratifying. Marked hyperactivity and 
aggressivity had not been their chief problems. The drug slowed them physically and 
mentally without solving the underlying problems. Reduction in activity is often quite 
disturbing to persons who have neurotically determined needs to be very active and 
constantly productive or to persons who realistically must do considerable physical or 
mental work, such as a mother of a large family or a business executive. In addition, 
the drug frequently causes unpleasant nasal stuffiness and occasionally aggravates 
depressions. Therefore, as a drug to produce psychologic peace, Rauwolfia compounds 
leave much to be desired and have been totally discarded from my practice. 
PHENOTHI /^ INE COMPOUNDS 
Probably the best known member of this group today is chlorpromazine (Thora-
zine). Initially, there was optimism concerning its curative abilities. Subsequent 
critical controlled studies have shown that it is very helpful in controlling agitation 
and combativeness but that it is otherwise rather ineffective in either psychotic or 
neurotic individuals. Side reactions, including jaundice, allergic reactions, parkinsonism, 
and aggravated depressions occur in up to 25 per cent of treated patients making it 
too dangerous for use except in special cases. A new analogue. Compazine (proclor-
perazine), is just being introduced with claims of lower toxicity. From my limited 
observations Compazine is much less potent and relatively ineffectual in disturbed 
patients. It may be helpful in mild anxiety states. 
Another member of this group is promazine (Sparine) in which the chlorine 
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radical has been omitted. This drug is avaflable in tablets of 25 mgm., 50 mgm., and 
100 mgm. and in an injectable form for either intravenous or intramuscular administra-
tion. I have also been using this medication in a capsule form made up so that one 
cannot tell the difference between any of these strengths nor of a corresponding placebo. 
According to animal experimentation, it was expected that larger doses of this drug 
than of chlorpromazine would be necessary, but I have found it of about equal 
effectiveness mifligram for milligram. The dosage is not fixed and patients have been 
maintained on as much as 800 mgms, daily for five months without untoward effect. 
However, increasing the dosage beyond 400 mgm. per day usually does not prove 
worth-while. 
Twenty-two patients suffering from many types of nervous disorder, mostly chronic 
psychoneuroses, were given promazine. Of the twenty-two, thirteen appeared to be 
helped, but seven of these felt just as well on a placebo. Of the six who could be said 
to have been helped by the medication, three were suffering acute disturbances with 
marked hyperactivity, aranoid delusions in two of these three were not relieved by 
the medication, but were relieved by electro-shock therapy. Among the other three 
persons helped was a chronic obsessive-compulsive housewife with a great deal of 
tension. She stated, "The medicine slows me down, relaxes me — I don't drive myself 
so." However, she continued to have many of her other complaints. Another obsessive 
person retained her obsessions but was less jittery. And finally, a disorganized 
ambulatory schizophrenic woman became more relaxed and more effective. Three 
patients developed weird "hysterical" symptoms upon taking the drug and also upon 
taking the placebo, so that nothing can be said concerning the efficacy of the medica-
tion in these individuals. Previously I have seen the hypomanic behavior of a manic-
depressive executive decreased to a point where he was able to continue his normal 
duties. In such cases, the dosage must be adjusted frequently according to the severity 
of the hypomania. 
Promazine has also proven helpful in quieting the acutely psychotic hyperactive 
individual, the acutely disturbed alcoholic, and the drug addict during the period of 
removal from the drug. Occasionally it will also be helpful in the more chronic dis-
turbances. This drug wifl potentiate barbiturates so that their concomitant use must 
be watched closely. The drug also causes hypotension. Here it should be noted that 
epinephrine should not be used to alleviate this, but rather nor-epinephrine. So far, 
somnolence has been the only side reaction and this may be controlled by reducing the 
dosage. Promazine appears to be more desirable than Chlorpromazine and the results 
appear comparable. 
MEPROBAMATE 
On radio, television, and in various publications Meprobamate has been described 
as "the happy pflls"; never has a drug been so widely demanded by the populace. It 
has been advertised to relax skeletal muscles, to produce a mild anticonvulsant activity, 
and primarfly to tranquflize without sedating. Our experience with psychiatric patients 
fafls to indicate that such enthusiasm is warranted. We have found it too mfld to 
control effectively acutely disturbed individuals. In 10-15 per cent of the chronic 
anxiety or tension states, obsessional neuroses, or conversion reactions we did find it 
helpful but the majority of patients do not show any more improvement than with a 
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placebo. They may improve temporarily only to have their symptoms return shortly 
and to discover that, like the many other remedies they have tried, Meprobamate is 
not solving their problems and giving peace. 
Meprobamate has so far been free of serious side reactions. An occasional patient 
may developed some dermatologic response, complain of blurring of vision, or complain 
of being too drowsy (despite the statement that they "tranquflize without sedating"). 
On rare occasions, patients have reacted with increased excitement. With large over-
doses a person becomes completely flaccid and deeply comatose for as long as forty-
eight hours. I f an adequate airway is maintained and fluid balance is preserved, he 
wifl, with no other treatment, gradually return to normal. There has recently been a 
report indicating that the drug may be definitely habit forming in a small per cent of 
users and lead to excessive self-medication, somnolence, or a state resembling intoxica-
tion. Some of these persons have exhibited mild withdrawal symptoms when the 
medication was withdrawn. This does indicate that supervision is necessary when 
giving this medication. Certainly, it is a drug that might be tried, but with the 
knowledge that only a small per cent are really going to benefit. 
Summary: 
New medications to reduce anxiety are appearing daily. The clinical responses 
to a few of these are reported. None of these drugs are cures but may be useful 
crutches. The patient should always be evaluated to determine if psychotheraphy might 
not be more helpful in a curative direction. 
BIBLIOGRAPHY 
1. Fabing, H, D,: Frenquel, a blocking agent against experimental LSD—25 and mescaline 
psychosis; preliminary note on its clinical application. Neurology 5:319, 1955. 
2. Lemere, F.: Failure of Azacyclonal (frenquel) to relieve nonexperimental mental confusion 
and hallucinations. Am. J. Psychiat. 113:840, 1957, 
3. Rinaldi, F,, Rudy, L. H. and Himwich, H, E,: The use of frenquel in the treatment of 
disturbed patients with psychoses of long duration. Am, J, Psychiat, 112:343, 1955, 
132 
